<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064789</url>
  </required_header>
  <id_info>
    <org_study_id>IP-01-2016</org_study_id>
    <nct_id>NCT03064789</nct_id>
  </id_info>
  <brief_title>Epidemiological Study in Subjects With Vulvovaginal Candidiases</brief_title>
  <official_title>Estudio epidemiológico de la evolución clínica y microbiológica en Pacientes Tratadas Por un Episodio Agudo de Candidiasis Vulvovaginal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Santiago Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiological study about the clinical and microbiological progress in subjects under&#xD;
      treatment for a severe vulvovaginal candidiases episody&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2016</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">March 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate cure rate in women with severe vuvovaginal candidiases infection</measure>
    <time_frame>At 3 months</time_frame>
    <description>Women must require antimicotic treatment plus vaginal probiotic following the habitual therapeutic standards</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate recurrences</measure>
    <time_frame>At 6 months</time_frame>
    <description>It will be consider recurrences an asymptomatic period for 7-10 days and a negative culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate recurrences</measure>
    <time_frame>At 12 months</time_frame>
    <description>It will be consider recurrences an asymptomatic period for 7-10 days and a negative culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the link between symptomatology and negative culture</measure>
    <time_frame>At 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of probiotic treatment by physician</measure>
    <time_frame>At 3 months</time_frame>
    <description>A gynecological exploration will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of probiotic treatment by patient. A satisfaction questionnaire will be performed</measure>
    <time_frame>At 3 months</time_frame>
    <description>The subject will be asked how long the symptoms lasted and the gravity of them</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Vulvovaginal Candidiases</condition>
  <arm_group>
    <arm_group_label>Women with candidiases infection</arm_group_label>
    <description>Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women with VVC symptomatology and positive culture&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sexually active women between 18 and 50 years of age at time of screening&#xD;
&#xD;
          -  With diagnosis and symptomatology of VVC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Women witihin three months after a delivery or misbirth&#xD;
&#xD;
          -  Women with vaginal or genital infection symptomatology other than candidiases that&#xD;
             needs antibiotic treatment&#xD;
&#xD;
          -  Vaginal probiotics use within last three months&#xD;
&#xD;
          -  Undiagnosed abnormal genital hemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Palacios, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Palacios</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Palacios</investigator_affiliation>
    <investigator_full_name>Dr. Santiago Palacios</investigator_full_name>
    <investigator_title>MD - Gynecologyst</investigator_title>
  </responsible_party>
  <keyword>Candidiases</keyword>
  <keyword>Vaginal Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

